<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03429556</url>
  </required_header>
  <id_info>
    <org_study_id>EB001-ABD201</org_study_id>
    <nct_id>NCT03429556</nct_id>
  </id_info>
  <brief_title>Study to Evaluate Botulinum Neurotoxin Serotype E (EB-001) in Reducing Musculoskeletal Pain in Abdominoplasty</brief_title>
  <official_title>A Phase 2 Study to Evaluate Safety and Efficacy of EB-001 Intramuscular (IM) Injections in Reducing Musculoskeletal Pain in Subjects Undergoing Elective Abdominoplasty Surgery</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Allergan</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Allergan</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      To determine the safety and efficacy of single intra-operative treatment of Botulinum
      Neurotoxin Serotype E (EB-001) intramuscular (IM) injections into the Rectus Abdominus (RA)
      in participants undergoing abdominoplasty.
    </textblock>
  </brief_summary>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    Sponsor decision to terminate early
  </why_stopped>
  <start_date type="Actual">May 8, 2018</start_date>
  <completion_date type="Actual">July 10, 2018</completion_date>
  <primary_completion_date type="Actual">July 10, 2018</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Area Under the Curve (AUC) of Participant's Assessment of Pain Using the Numerical Pain Rating Scale (NPRS) at Rest Between 12 and 96 Hours Postsurgery (AUC12-96)</measure>
    <time_frame>Every 2 hours from 12 to 96 hours postsurgery</time_frame>
    <description>The participant assessed their current pain using the 11-point NPRS where: 0=no pain to 10=worst pain imaginable. AUC was calculated using the standard trapezoidal rule.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>AUC of Participant's Assessment of Pain Using the NPRS at Rest Between 0 and 96 Hours Postsurgery</measure>
    <time_frame>Every 2 hours from 0 to 96 hours postsurgery</time_frame>
    <description>The participant assessed their current pain using the 11-point NPRS where: 0=no pain to 10=worst pain imaginable. AUC was calculated using the standard trapezoidal rule.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>AUC of Participant's Assessment of Pain Using the NPRS at Rest Between 0 and 72 Hours Postsurgery (AUC0-72)</measure>
    <time_frame>Every 2 hours from 0 to 72 hours postsurgery</time_frame>
    <description>The participant assessed their current pain using the 11-point NPRS where: 0=no pain to 10=worst pain imaginable. AUC was calculated using the standard trapezoidal rule.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>AUC of Participant's Assessment of Pain Using the NPRS at Rest Between 0 and 48 Hours Postsurgery (AUC0-48)</measure>
    <time_frame>Every 2 hours from 0 to 48 hours postsurgery</time_frame>
    <description>The participant assessed their current pain using the 11-point NPRS where: 0=no pain to 10=worst pain imaginable. AUC was calculated using the standard trapezoidal rule.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>AUC of Participant's Assessment of Pain Using the NPRS at Rest Between 0 and 24 Hours Postsurgery (AUC0-24)</measure>
    <time_frame>Every 2 hours from 0 to 24 hours postsurgery</time_frame>
    <description>The participant assessed their current pain using the 11-point NPRS where: 0=no pain to 10=worst pain imaginable. AUC was calculated using the standard trapezoidal rule.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>AUC of Participant's Assessment of Pain Using the NPRS at Rest Between 12 and 24 Hours Postsurgery (AUC12-24)</measure>
    <time_frame>Every 2 hours from 12 to 24 hours postsurgery</time_frame>
    <description>The participant assessed their current pain using the 11-point NPRS where: 0=no pain to 10=worst pain imaginable. AUC was calculated using the standard trapezoidal rule.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Participants Overall Assessment of Pain Using the NPRS After Discharge</measure>
    <time_frame>Days 6, 7, 8, 9, 10, 11, 12, 13, 14, 16, 18, 20, 22, 24 and 26</time_frame>
    <description>The participant assessed their pain after discharge using the 11-point NPRS where: 0=no pain to 10=worst pain imaginable.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Participant's Overall Assessment of Pain Using the NPRS-Activity (NPRS-A)</measure>
    <time_frame>8, 16, 24, 30, 36, 42, 48, 54, 60, 66, 72.78.84, and 96 hours after surgery; Days 8, 15 and 29 after discharge</time_frame>
    <description>The participant assessed their pain using the 11-point NPRS-A, after sitting up in the bed unassisted at an angle of approximately â‰¥ 45 degrees, swinging legs out, putting feet down, standing up, and walking approximately 10 feet, where: 0=no pain to 10=worst pain imaginable.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants by Patient Global Assessment (PGA) of Pain Control Score Categories</measure>
    <time_frame>Days 5, 8, 15 and 29</time_frame>
    <description>The participant assessed their overall pain control in the past 24 hours using the PGA 4-point scale where: 0=poor, 1=fair, 2=good and 3=excellent.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Doses of Rescue Medications Used</measure>
    <time_frame>Up to 96 hours postsurgery</time_frame>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Actual">23</enrollment>
  <condition>Abdominoplasty</condition>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo (sterile saline solution 0.9% Sodium Chloride Injection) injected into RA muscles during abdominoplasty surgery.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Botulinum Neurotoxin Serotype E Dose 1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Single botulinum neurotoxin serotype E Dose 1 injection into RA muscles during abdominoplasty surgery.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Botulinum Neurotoxin Serotype E Dose 2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Single botulinum neurotoxin serotype E Dose 2 injection into RA muscles during abdominoplasty surgery.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Botulinum Neurotoxin Serotype E Dose 3</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Single botulinum neurotoxin serotype E Dose 3 injection into RA muscles during abdominoplasty surgery.</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Botulinum Neurotoxin Serotype E</intervention_name>
    <description>Single botulinum neurotoxin serotype E injection into RA muscles during abdominoplasty surgery.</description>
    <arm_group_label>Botulinum Neurotoxin Serotype E Dose 1</arm_group_label>
    <arm_group_label>Botulinum Neurotoxin Serotype E Dose 2</arm_group_label>
    <arm_group_label>Botulinum Neurotoxin Serotype E Dose 3</arm_group_label>
    <other_name>EB-001</other_name>
    <other_name>BoNT/E</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Placebo (sterile saline solution 0.9% Sodium Chloride Injection) injected into RA muscles during abdominoplasty surgery.</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Men or women 23 to 55 years of age, inclusive

          2. Scheduled to undergo elective abdominoplasty surgery with full length plication from
             xyphoid to pubis, and removal of skin/fat flap under general anesthesia (endotracheal
             or otherwise) without liposuction

          3. American Society of Anesthesiologist (ASA) Physical Class 1-2.

        Exclusion Criteria:

          1. History of prior major abdominal surgery as judged by the investigator

          2. Pre-existing lung disease that could impact participant safety in the opinion of the
             investigator

          3. Pre-existing disorders of the neuromuscular junction (myasthenia gravis, Eaton-
             Lambert syndrome, or amyotrophic lateral Sclerosis)

          4. At high risk of deep vein thrombosis as judged by the investigators determined by a
             Caprini score of 3 or higher

          5. Slow vital capacity that is below 80% of normal value for respective race, age,
             height, and gender or below 2.5 Liters (L) of absolute volume

          6. Pulse oximetry below 95%

          7. Body weight less than 50 kg (110 pounds) or a Body Mass Index (BMI) of â‰¥ 32

          8. Reported use of any botulinum toxin within 3 months prior to the date of surgery

          9. Use of long acting opioids within 3 days or any opioid medication within 24 hours
             prior to surgery

         10. Aminoglycoside intake within 48 hours prior to or during surgery

         11. Participants on anti-depressant or anti-psychotic medications

         12. Reported pain score of 2 or more at screening on the 11-point scale numerical pain
             rating scale-administered after an activity (NPRS-A) following an activity after and
             walking approximately 10 feet.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>23 Years</minimum_age>
    <maximum_age>55 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Joan-En Lin</last_name>
    <role>Study Director</role>
    <affiliation>Allergan</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Huntington Ambulatory Surgery Center</name>
      <address>
        <city>Pasadena</city>
        <state>California</state>
        <zip>91105</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Lotus Clinical Research, LLC</name>
      <address>
        <city>Pasadena</city>
        <state>California</state>
        <zip>91105</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>August 2019</verification_date>
  <study_first_submitted>February 6, 2018</study_first_submitted>
  <study_first_submitted_qc>February 6, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">February 12, 2018</study_first_posted>
  <results_first_submitted>July 2, 2019</results_first_submitted>
  <results_first_submitted_qc>August 1, 2019</results_first_submitted_qc>
  <results_first_posted type="Actual">August 5, 2019</results_first_posted>
  <last_update_submitted>August 1, 2019</last_update_submitted>
  <last_update_submitted_qc>August 1, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">August 5, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>pain, neurotoxin</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Musculoskeletal Pain</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <provided_document_section>
    <provided_document>
      <document_type>Study Protocol</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>No</document_has_sap>
      <document_date>September 28, 2018</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/56/NCT03429556/Prot_000.pdf</document_url>
    </provided_document>
    <provided_document>
      <document_type>Statistical Analysis Plan</document_type>
      <document_has_protocol>No</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>Yes</document_has_sap>
      <document_date>May 9, 2018</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/56/NCT03429556/SAP_001.pdf</document_url>
    </provided_document>
  </provided_document_section>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Placebo</title>
          <description>Placebo (sterile saline solution 0.9% Sodium Chloride Injection) injected into rectus abdominus (RA) muscles during abdominoplasty surgery.</description>
        </group>
        <group group_id="P2">
          <title>Botulinum Neurotoxin Serotype E Dose 1</title>
          <description>Single botulinum neurotoxin serotype E Dose 1 injection into RA muscles during abdominoplasty surgery.</description>
        </group>
        <group group_id="P3">
          <title>Botulinum Neurotoxin Serotype E Dose 2</title>
          <description>Single botulinum neurotoxin serotype E Dose 2 injection into RA muscles during abdominoplasty surgery.</description>
        </group>
        <group group_id="P4">
          <title>Botulinum Neurotoxin Serotype E Dose 3</title>
          <description>Single botulinum neurotoxin serotype E Dose 3 injection into RA muscles during abdominoplasty surgery.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="12"/>
                <participants group_id="P2" count="4"/>
                <participants group_id="P3" count="4"/>
                <participants group_id="P4" count="3"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="12"/>
                <participants group_id="P2" count="3"/>
                <participants group_id="P3" count="4"/>
                <participants group_id="P4" count="3"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <population>Safety Population included all participants exposed to any amount of study drug.</population>
      <group_list>
        <group group_id="B1">
          <title>Placebo</title>
          <description>Placebo (sterile saline solution 0.9% Sodium Chloride Injection) injected into RA muscles during abdominoplasty surgery.</description>
        </group>
        <group group_id="B2">
          <title>Botulinum Neurotoxin Serotype E Dose 1</title>
          <description>Single botulinum neurotoxin serotype E Dose 1 injection into RA muscles during abdominoplasty surgery.</description>
        </group>
        <group group_id="B3">
          <title>Botulinum Neurotoxin Serotype E Dose 2</title>
          <description>Single botulinum neurotoxin serotype E Dose 2 injection into RA muscles during abdominoplasty surgery.</description>
        </group>
        <group group_id="B4">
          <title>Botulinum Neurotoxin Serotype E Dose 3</title>
          <description>Single botulinum neurotoxin serotype E Dose 3 injection into RA muscles during abdominoplasty surgery.</description>
        </group>
        <group group_id="B5">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="12"/>
            <count group_id="B2" value="4"/>
            <count group_id="B3" value="4"/>
            <count group_id="B4" value="3"/>
            <count group_id="B5" value="23"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="36.5" spread="5.2"/>
                    <measurement group_id="B2" value="33.0" spread="6.38"/>
                    <measurement group_id="B3" value="36.3" spread="7.72"/>
                    <measurement group_id="B4" value="41.0" spread="14.0"/>
                    <measurement group_id="B5" value="36.7" spread="3.29"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="11"/>
                    <measurement group_id="B2" value="4"/>
                    <measurement group_id="B3" value="4"/>
                    <measurement group_id="B4" value="3"/>
                    <measurement group_id="B5" value="22"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race/Ethnicity, Customized</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Asian</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="1"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="1"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Black or African American</title>
                  <measurement_list>
                    <measurement group_id="B1" value="5"/>
                    <measurement group_id="B2" value="3"/>
                    <measurement group_id="B3" value="1"/>
                    <measurement group_id="B4" value="2"/>
                    <measurement group_id="B5" value="11"/>
                  </measurement_list>
                </category>
                <category>
                  <title>White or Caucasian</title>
                  <measurement_list>
                    <measurement group_id="B1" value="6"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="2"/>
                    <measurement group_id="B4" value="1"/>
                    <measurement group_id="B5" value="10"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Other/Mixed</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race/Ethnicity, Customized</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="6"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="2"/>
                    <measurement group_id="B4" value="1"/>
                    <measurement group_id="B5" value="10"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Not Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="6"/>
                    <measurement group_id="B2" value="3"/>
                    <measurement group_id="B3" value="2"/>
                    <measurement group_id="B4" value="2"/>
                    <measurement group_id="B5" value="13"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Area Under the Curve (AUC) of Participant's Assessment of Pain Using the Numerical Pain Rating Scale (NPRS) at Rest Between 12 and 96 Hours Postsurgery (AUC12-96)</title>
        <description>The participant assessed their current pain using the 11-point NPRS where: 0=no pain to 10=worst pain imaginable. AUC was calculated using the standard trapezoidal rule.</description>
        <time_frame>Every 2 hours from 12 to 96 hours postsurgery</time_frame>
        <population>Modified Intent-to-treat (mITT) population included all randomized and treated participants with at least one post-injection pain score.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Placebo (sterile saline solution 0.9% Sodium Chloride Injection) injected into RA muscles during abdominoplasty surgery.</description>
          </group>
          <group group_id="O2">
            <title>Botulinum Neurotoxin Serotype E Dose 1</title>
            <description>Single botulinum neurotoxin serotype E Dose 1 injection into RA muscles during abdominoplasty surgery.</description>
          </group>
          <group group_id="O3">
            <title>Botulinum Neurotoxin Serotype E Dose 2</title>
            <description>Single botulinum neurotoxin serotype E Dose 2 injection into RA muscles during abdominoplasty surgery.</description>
          </group>
          <group group_id="O4">
            <title>Botulinum Neurotoxin Serotype E Dose 3</title>
            <description>Single botulinum neurotoxin serotype E Dose 3 injection into RA muscles during abdominoplasty surgery.</description>
          </group>
        </group_list>
        <measure>
          <title>Area Under the Curve (AUC) of Participant's Assessment of Pain Using the Numerical Pain Rating Scale (NPRS) at Rest Between 12 and 96 Hours Postsurgery (AUC12-96)</title>
          <description>The participant assessed their current pain using the 11-point NPRS where: 0=no pain to 10=worst pain imaginable. AUC was calculated using the standard trapezoidal rule.</description>
          <population>Modified Intent-to-treat (mITT) population included all randomized and treated participants with at least one post-injection pain score.</population>
          <units>hour (hr)*score on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="11"/>
                <count group_id="O2" value="1"/>
                <count group_id="O3" value="4"/>
                <count group_id="O4" value="3"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="321.18" spread="217.993"/>
                    <measurement group_id="O2" value="209.30" spread="NA">Standard deviation (SD) was not calculated for 1 participant.</measurement>
                    <measurement group_id="O3" value="415.40" spread="124.101"/>
                    <measurement group_id="O4" value="372.53" spread="135.799"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>AUC of Participant's Assessment of Pain Using the NPRS at Rest Between 0 and 96 Hours Postsurgery</title>
        <description>The participant assessed their current pain using the 11-point NPRS where: 0=no pain to 10=worst pain imaginable. AUC was calculated using the standard trapezoidal rule.</description>
        <time_frame>Every 2 hours from 0 to 96 hours postsurgery</time_frame>
        <population>mITT population included all randomized and treated participants with at least one post-injection pain score.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Placebo (sterile saline solution 0.9% Sodium Chloride Injection) injected into RA muscles during abdominoplasty surgery.</description>
          </group>
          <group group_id="O2">
            <title>Botulinum Neurotoxin Serotype E Dose 1</title>
            <description>Single botulinum neurotoxin serotype E Dose 1 injection into RA muscles during abdominoplasty surgery.</description>
          </group>
          <group group_id="O3">
            <title>Botulinum Neurotoxin Serotype E Dose 2</title>
            <description>Single botulinum neurotoxin serotype E Dose 2 injection into RA muscles during abdominoplasty surgery.</description>
          </group>
          <group group_id="O4">
            <title>Botulinum Neurotoxin Serotype E Dose 3</title>
            <description>Single botulinum neurotoxin serotype E Dose 3 injection into RA muscles during abdominoplasty surgery.</description>
          </group>
        </group_list>
        <measure>
          <title>AUC of Participant's Assessment of Pain Using the NPRS at Rest Between 0 and 96 Hours Postsurgery</title>
          <description>The participant assessed their current pain using the 11-point NPRS where: 0=no pain to 10=worst pain imaginable. AUC was calculated using the standard trapezoidal rule.</description>
          <population>mITT population included all randomized and treated participants with at least one post-injection pain score.</population>
          <units>hr*score on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="11"/>
                <count group_id="O2" value="1"/>
                <count group_id="O3" value="4"/>
                <count group_id="O4" value="3"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="403.80" spread="229.152"/>
                    <measurement group_id="O2" value="282.50" spread="NA">SD was not calculated for 1 participant.</measurement>
                    <measurement group_id="O3" value="506.83" spread="130.598"/>
                    <measurement group_id="O4" value="450.97" spread="139.769"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>AUC of Participant's Assessment of Pain Using the NPRS at Rest Between 0 and 72 Hours Postsurgery (AUC0-72)</title>
        <description>The participant assessed their current pain using the 11-point NPRS where: 0=no pain to 10=worst pain imaginable. AUC was calculated using the standard trapezoidal rule.</description>
        <time_frame>Every 2 hours from 0 to 72 hours postsurgery</time_frame>
        <population>mITT population included all randomized and treated participants with at least one post-injection pain score.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Placebo (sterile saline solution 0.9% Sodium Chloride Injection) injected into RA muscles during abdominoplasty surgery.</description>
          </group>
          <group group_id="O2">
            <title>Botulinum Neurotoxin Serotype E Dose 1</title>
            <description>Single botulinum neurotoxin serotype E Dose 1 injection into RA muscles during abdominoplasty surgery.</description>
          </group>
          <group group_id="O3">
            <title>Botulinum Neurotoxin Serotype E Dose 2</title>
            <description>Single botulinum neurotoxin serotype E Dose 2 injection into RA muscles during abdominoplasty surgery.</description>
          </group>
          <group group_id="O4">
            <title>Botulinum Neurotoxin Serotype E Dose 3</title>
            <description>Single botulinum neurotoxin serotype E Dose 3 injection into RA muscles during abdominoplasty surgery.</description>
          </group>
        </group_list>
        <measure>
          <title>AUC of Participant's Assessment of Pain Using the NPRS at Rest Between 0 and 72 Hours Postsurgery (AUC0-72)</title>
          <description>The participant assessed their current pain using the 11-point NPRS where: 0=no pain to 10=worst pain imaginable. AUC was calculated using the standard trapezoidal rule.</description>
          <population>mITT population included all randomized and treated participants with at least one post-injection pain score.</population>
          <units>hr*score on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="11"/>
                <count group_id="O2" value="1"/>
                <count group_id="O3" value="4"/>
                <count group_id="O4" value="3"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="338.91" spread="173.785"/>
                    <measurement group_id="O2" value="280.50" spread="NA">SD was not calculated for 1 participant.</measurement>
                    <measurement group_id="O3" value="416.70" spread="97.464"/>
                    <measurement group_id="O4" value="372.47" spread="86.226"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>AUC of Participant's Assessment of Pain Using the NPRS at Rest Between 0 and 48 Hours Postsurgery (AUC0-48)</title>
        <description>The participant assessed their current pain using the 11-point NPRS where: 0=no pain to 10=worst pain imaginable. AUC was calculated using the standard trapezoidal rule.</description>
        <time_frame>Every 2 hours from 0 to 48 hours postsurgery</time_frame>
        <population>mITT population included all randomized and treated participants with at least one post-injection pain score.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Placebo (sterile saline solution 0.9% Sodium Chloride Injection) injected into RA muscles during abdominoplasty surgery.</description>
          </group>
          <group group_id="O2">
            <title>Botulinum Neurotoxin Serotype E Dose 1</title>
            <description>Single botulinum neurotoxin serotype E Dose 1 injection into RA muscles during abdominoplasty surgery.</description>
          </group>
          <group group_id="O3">
            <title>Botulinum Neurotoxin Serotype E Dose 2</title>
            <description>Single botulinum neurotoxin serotype E Dose 2 injection into RA muscles during abdominoplasty surgery.</description>
          </group>
          <group group_id="O4">
            <title>Botulinum Neurotoxin Serotype E Dose 3</title>
            <description>Single botulinum neurotoxin serotype E Dose 3 injection into RA muscles during abdominoplasty surgery.</description>
          </group>
        </group_list>
        <measure>
          <title>AUC of Participant's Assessment of Pain Using the NPRS at Rest Between 0 and 48 Hours Postsurgery (AUC0-48)</title>
          <description>The participant assessed their current pain using the 11-point NPRS where: 0=no pain to 10=worst pain imaginable. AUC was calculated using the standard trapezoidal rule.</description>
          <population>mITT population included all randomized and treated participants with at least one post-injection pain score.</population>
          <units>hr*score on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="11"/>
                <count group_id="O2" value="1"/>
                <count group_id="O3" value="4"/>
                <count group_id="O4" value="3"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="253.53" spread="106.862"/>
                    <measurement group_id="O2" value="240.80" spread="NA">SD was not calculated for 1 participant.</measurement>
                    <measurement group_id="O3" value="283.20" spread="60.450"/>
                    <measurement group_id="O4" value="274.47" spread="32.686"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>AUC of Participant's Assessment of Pain Using the NPRS at Rest Between 0 and 24 Hours Postsurgery (AUC0-24)</title>
        <description>The participant assessed their current pain using the 11-point NPRS where: 0=no pain to 10=worst pain imaginable. AUC was calculated using the standard trapezoidal rule.</description>
        <time_frame>Every 2 hours from 0 to 24 hours postsurgery</time_frame>
        <population>mITT population included all randomized and treated participants with at least one post-injection pain score.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Placebo (sterile saline solution 0.9% Sodium Chloride Injection) injected into RA muscles during abdominoplasty surgery.</description>
          </group>
          <group group_id="O2">
            <title>Botulinum Neurotoxin Serotype E Dose 1</title>
            <description>Single botulinum neurotoxin serotype E Dose 1 injection into RA muscles during abdominoplasty surgery.</description>
          </group>
          <group group_id="O3">
            <title>Botulinum Neurotoxin Serotype E Dose 2</title>
            <description>Single botulinum neurotoxin serotype E Dose 2 injection into RA muscles during abdominoplasty surgery.</description>
          </group>
          <group group_id="O4">
            <title>Botulinum Neurotoxin Serotype E Dose 3</title>
            <description>Single botulinum neurotoxin serotype E Dose 3 injection into RA muscles during abdominoplasty surgery.</description>
          </group>
        </group_list>
        <measure>
          <title>AUC of Participant's Assessment of Pain Using the NPRS at Rest Between 0 and 24 Hours Postsurgery (AUC0-24)</title>
          <description>The participant assessed their current pain using the 11-point NPRS where: 0=no pain to 10=worst pain imaginable. AUC was calculated using the standard trapezoidal rule.</description>
          <population>mITT population included all randomized and treated participants with at least one post-injection pain score.</population>
          <units>hr*score on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="11"/>
                <count group_id="O2" value="1"/>
                <count group_id="O3" value="4"/>
                <count group_id="O4" value="3"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="144.49" spread="46.693"/>
                    <measurement group_id="O2" value="149.80" spread="NA">The SD was not calculated due to less number of participants with data.</measurement>
                    <measurement group_id="O3" value="155.53" spread="28.726"/>
                    <measurement group_id="O4" value="146.30" spread="21.717"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>AUC of Participant's Assessment of Pain Using the NPRS at Rest Between 12 and 24 Hours Postsurgery (AUC12-24)</title>
        <description>The participant assessed their current pain using the 11-point NPRS where: 0=no pain to 10=worst pain imaginable. AUC was calculated using the standard trapezoidal rule.</description>
        <time_frame>Every 2 hours from 12 to 24 hours postsurgery</time_frame>
        <population>mITT population included all randomized and treated participants with at least one post-injection pain score.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Placebo (sterile saline solution 0.9% Sodium Chloride Injection) injected into RA muscles during abdominoplasty surgery.</description>
          </group>
          <group group_id="O2">
            <title>Botulinum Neurotoxin Serotype E Dose 1</title>
            <description>Single botulinum neurotoxin serotype E Dose 1 injection into RA muscles during abdominoplasty surgery.</description>
          </group>
          <group group_id="O3">
            <title>Botulinum Neurotoxin Serotype E Dose 2</title>
            <description>Single botulinum neurotoxin serotype E Dose 2 injection into RA muscles during abdominoplasty surgery.</description>
          </group>
          <group group_id="O4">
            <title>Botulinum Neurotoxin Serotype E Dose 3</title>
            <description>Single botulinum neurotoxin serotype E Dose 3 injection into RA muscles during abdominoplasty surgery.</description>
          </group>
        </group_list>
        <measure>
          <title>AUC of Participant's Assessment of Pain Using the NPRS at Rest Between 12 and 24 Hours Postsurgery (AUC12-24)</title>
          <description>The participant assessed their current pain using the 11-point NPRS where: 0=no pain to 10=worst pain imaginable. AUC was calculated using the standard trapezoidal rule.</description>
          <population>mITT population included all randomized and treated participants with at least one post-injection pain score.</population>
          <units>hr*score on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="11"/>
                <count group_id="O2" value="1"/>
                <count group_id="O3" value="4"/>
                <count group_id="O4" value="3"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="61.91" spread="32.210"/>
                    <measurement group_id="O2" value="76.60" spread="NA">SD was not calculated for 1 participant.</measurement>
                    <measurement group_id="O3" value="64.10" spread="22.825"/>
                    <measurement group_id="O4" value="67.83" spread="18.827"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Participants Overall Assessment of Pain Using the NPRS After Discharge</title>
        <description>The participant assessed their pain after discharge using the 11-point NPRS where: 0=no pain to 10=worst pain imaginable.</description>
        <time_frame>Days 6, 7, 8, 9, 10, 11, 12, 13, 14, 16, 18, 20, 22, 24 and 26</time_frame>
        <population>mITT population included all randomized and treated participants with at least one post-injection pain score.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Placebo (sterile saline solution 0.9% Sodium Chloride Injection) injected into RA muscles during abdominoplasty surgery.</description>
          </group>
          <group group_id="O2">
            <title>Botulinum Neurotoxin Serotype E Dose 1</title>
            <description>Single botulinum neurotoxin serotype E Dose 1 injection into RA muscles during abdominoplasty surgery.</description>
          </group>
          <group group_id="O3">
            <title>Botulinum Neurotoxin Serotype E Dose 2</title>
            <description>Single botulinum neurotoxin serotype E Dose 2 injection into RA muscles during abdominoplasty surgery.</description>
          </group>
          <group group_id="O4">
            <title>Botulinum Neurotoxin Serotype E Dose 3</title>
            <description>Single botulinum neurotoxin serotype E Dose 3 injection into RA muscles during abdominoplasty surgery.</description>
          </group>
        </group_list>
        <measure>
          <title>Participants Overall Assessment of Pain Using the NPRS After Discharge</title>
          <description>The participant assessed their pain after discharge using the 11-point NPRS where: 0=no pain to 10=worst pain imaginable.</description>
          <population>mITT population included all randomized and treated participants with at least one post-injection pain score.</population>
          <units>score on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="11"/>
                <count group_id="O2" value="1"/>
                <count group_id="O3" value="4"/>
                <count group_id="O4" value="3"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Day 6</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.3" spread="1.66"/>
                    <measurement group_id="O2" value="0.0" spread="NA">SD was not calculated for 1 participant.</measurement>
                    <measurement group_id="O3" value="6.0" spread="1.83"/>
                    <measurement group_id="O4" value="2.3" spread="2.08"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 7</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.3" spread="2.78"/>
                    <measurement group_id="O2" value="0.0" spread="NA">SD was not calculated for 1 participant.</measurement>
                    <measurement group_id="O3" value="3.8" spread="0.50"/>
                    <measurement group_id="O4" value="3.0" spread="3.00"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 8</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.8" spread="1.79"/>
                    <measurement group_id="O2" value="0.0" spread="NA">SD was not calculated for 1 participant.</measurement>
                    <measurement group_id="O3" value="3.5" spread="1.73"/>
                    <measurement group_id="O4" value="3.0" spread="3.00"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 9</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.1" spread="2.62"/>
                    <measurement group_id="O2" value="0.0" spread="NA">SD was not calculated for 1 participant.</measurement>
                    <measurement group_id="O3" value="5.3" spread="1.50"/>
                    <measurement group_id="O4" value="1.5" spread="2.12"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 10</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.8" spread="1.92"/>
                    <measurement group_id="O2" value="0.0" spread="NA">SD was not calculated for 1 participant.</measurement>
                    <measurement group_id="O3" value="4.0" spread="0.82"/>
                    <measurement group_id="O4" value="1.5" spread="2.12"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 11</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.8" spread="2.28"/>
                    <measurement group_id="O2" value="0.0" spread="NA">SD was not calculated for 1 participant.</measurement>
                    <measurement group_id="O3" value="3.3" spread="1.50"/>
                    <measurement group_id="O4" value="1.5" spread="2.12"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 12</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.7" spread="1.87"/>
                    <measurement group_id="O2" value="0.0" spread="NA">SD was not calculated for 1 participant.</measurement>
                    <measurement group_id="O3" value="2.5" spread="1.29"/>
                    <measurement group_id="O4" value="1.5" spread="2.12"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 13</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.7" spread="1.73"/>
                    <measurement group_id="O2" value="0.0" spread="NA">SD was not calculated for 1 participant.</measurement>
                    <measurement group_id="O3" value="3.0" spread="0.00"/>
                    <measurement group_id="O4" value="2.0" spread="2.83"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 14</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.7" spread="1.94"/>
                    <measurement group_id="O2" value="0.0" spread="NA">SD was not calculated for 1 participant.</measurement>
                    <measurement group_id="O3" value="2.3" spread="1.71"/>
                    <measurement group_id="O4" value="2.0" spread="2.83"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 16</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.9" spread="2.47"/>
                    <measurement group_id="O2" value="0.0" spread="NA">SD was not calculated for 1 participant.</measurement>
                    <measurement group_id="O3" value="2.0" spread="0.82"/>
                    <measurement group_id="O4" value="1.5" spread="2.12"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 18</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.6" spread="2.26"/>
                    <measurement group_id="O2" value="0.0" spread="NA">SD was not calculated for 1 participant.</measurement>
                    <measurement group_id="O3" value="1.8" spread="0.96"/>
                    <measurement group_id="O4" value="1.5" spread="2.12"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 20</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.6" spread="2.20"/>
                    <measurement group_id="O2" value="0.0" spread="NA">SD was not calculated for 1 participant.</measurement>
                    <measurement group_id="O3" value="1.8" spread="0.96"/>
                    <measurement group_id="O4" value="1.5" spread="2.12"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 22</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.1" spread="1.73"/>
                    <measurement group_id="O2" value="0.0" spread="NA">SD was not calculated for 1 participant.</measurement>
                    <measurement group_id="O3" value="1.0" spread="1.41"/>
                    <measurement group_id="O4" value="1.5" spread="2.12"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 24</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.5" spread="2.45"/>
                    <measurement group_id="O2" value="0.0" spread="NA">SD was not calculated for 1 participant.</measurement>
                    <measurement group_id="O3" value="1.0" spread="1.41"/>
                    <measurement group_id="O4" value="2.0" spread="2.83"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 26</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.3" spread="1.98"/>
                    <measurement group_id="O2" value="0.0" spread="NA">SD was not calculated for 1 participant.</measurement>
                    <measurement group_id="O3" value="1.0" spread="1.41"/>
                    <measurement group_id="O4" value="1.5" spread="2.12"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Participant's Overall Assessment of Pain Using the NPRS-Activity (NPRS-A)</title>
        <description>The participant assessed their pain using the 11-point NPRS-A, after sitting up in the bed unassisted at an angle of approximately â‰¥ 45 degrees, swinging legs out, putting feet down, standing up, and walking approximately 10 feet, where: 0=no pain to 10=worst pain imaginable.</description>
        <time_frame>8, 16, 24, 30, 36, 42, 48, 54, 60, 66, 72.78.84, and 96 hours after surgery; Days 8, 15 and 29 after discharge</time_frame>
        <population>mITT population included all randomized and treated participants with at least one post-injection pain score. Participants analyzed is the number of participants with data available for analysis at the given time point.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Placebo (sterile saline solution 0.9% Sodium Chloride Injection) injected into RA muscles during abdominoplasty surgery.</description>
          </group>
          <group group_id="O2">
            <title>Botulinum Neurotoxin Serotype E Dose 1</title>
            <description>Single botulinum neurotoxin serotype E Dose 1 injection into RA muscles during abdominoplasty surgery.</description>
          </group>
          <group group_id="O3">
            <title>Botulinum Neurotoxin Serotype E Dose 2</title>
            <description>Single botulinum neurotoxin serotype E Dose 2 injection into RA muscles during abdominoplasty surgery.</description>
          </group>
          <group group_id="O4">
            <title>Botulinum Neurotoxin Serotype E Dose 3</title>
            <description>Single botulinum neurotoxin serotype E Dose 3 injection into RA muscles during abdominoplasty surgery.</description>
          </group>
        </group_list>
        <measure>
          <title>Participant's Overall Assessment of Pain Using the NPRS-Activity (NPRS-A)</title>
          <description>The participant assessed their pain using the 11-point NPRS-A, after sitting up in the bed unassisted at an angle of approximately â‰¥ 45 degrees, swinging legs out, putting feet down, standing up, and walking approximately 10 feet, where: 0=no pain to 10=worst pain imaginable.</description>
          <population>mITT population included all randomized and treated participants with at least one post-injection pain score. Participants analyzed is the number of participants with data available for analysis at the given time point.</population>
          <units>score on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="11"/>
                <count group_id="O2" value="1"/>
                <count group_id="O3" value="4"/>
                <count group_id="O4" value="3"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>8 hours after surgery</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="11"/>
                    <count group_id="O2" value="1"/>
                    <count group_id="O3" value="4"/>
                    <count group_id="O4" value="3"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6.9" spread="2.74"/>
                    <measurement group_id="O2" value="5.0" spread="NA">SD was not calculated for 1 participant.</measurement>
                    <measurement group_id="O3" value="6.0" spread="2.45"/>
                    <measurement group_id="O4" value="6.3" spread="0.58"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>16 hours after surgery</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="11"/>
                    <count group_id="O2" value="1"/>
                    <count group_id="O3" value="0"/>
                    <count group_id="O4" value="1"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="8.7" spread="1.53"/>
                    <measurement group_id="O2" value="4.0" spread="NA">SD was not calculated for 1 participant.</measurement>
                    <measurement group_id="O4" value="7.0" spread="NA">SD was not calculated for 1 participant.</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>24 hours after surgery</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="11"/>
                    <count group_id="O2" value="1"/>
                    <count group_id="O3" value="4"/>
                    <count group_id="O4" value="3"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6.6" spread="2.40"/>
                    <measurement group_id="O2" value="5.0" spread="NA">SD was not calculated for 1 participant.</measurement>
                    <measurement group_id="O3" value="7.5" spread="1.29"/>
                    <measurement group_id="O4" value="6.3" spread="0.58"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>30 hours after surgery</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="11"/>
                    <count group_id="O2" value="1"/>
                    <count group_id="O3" value="4"/>
                    <count group_id="O4" value="3"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6.5" spread="2.45"/>
                    <measurement group_id="O2" value="5.0" spread="NA">SD was not calculated for 1 participant.</measurement>
                    <measurement group_id="O3" value="7.0" spread="2.16"/>
                    <measurement group_id="O4" value="5.0" spread="2.00"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>36 hours after surgery</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="11"/>
                    <count group_id="O2" value="1"/>
                    <count group_id="O3" value="4"/>
                    <count group_id="O4" value="3"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6.3" spread="1.89"/>
                    <measurement group_id="O2" value="4.0" spread="NA">SD was not calculated for 1 participant.</measurement>
                    <measurement group_id="O3" value="6.5" spread="1.29"/>
                    <measurement group_id="O4" value="6.3" spread="0.58"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>42 hours after surgery</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="11"/>
                    <count group_id="O2" value="0"/>
                    <count group_id="O3" value="0"/>
                    <count group_id="O4" value="0"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5.8" spread="1.47"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>48 hours after surgery</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="11"/>
                    <count group_id="O2" value="1"/>
                    <count group_id="O3" value="4"/>
                    <count group_id="O4" value="3"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.3" spread="1.50"/>
                    <measurement group_id="O2" value="3.0" spread="NA">SD was not calculated for 1 participant.</measurement>
                    <measurement group_id="O3" value="5.3" spread="1.71"/>
                    <measurement group_id="O4" value="3.7" spread="1.53"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>54 hours after surgery</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="11"/>
                    <count group_id="O2" value="1"/>
                    <count group_id="O3" value="4"/>
                    <count group_id="O4" value="3"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.8" spread="1.20"/>
                    <measurement group_id="O2" value="2.0" spread="NA">SD was not calculated for 1 participant.</measurement>
                    <measurement group_id="O3" value="6.3" spread="3.10"/>
                    <measurement group_id="O4" value="4.0" spread="2.00"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>60 hours after surgery</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="11"/>
                    <count group_id="O2" value="1"/>
                    <count group_id="O3" value="4"/>
                    <count group_id="O4" value="3"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6.3" spread="2.75"/>
                    <measurement group_id="O2" value="3.0" spread="NA">SD was not calculated for 1 participant.</measurement>
                    <measurement group_id="O3" value="6.0" spread="1.41"/>
                    <measurement group_id="O4" value="3.3" spread="2.52"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>66 hours after surgery</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="11"/>
                    <count group_id="O2" value="0"/>
                    <count group_id="O3" value="0"/>
                    <count group_id="O4" value="0"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.7" spread="3.20"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>72 hours after surgery</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="11"/>
                    <count group_id="O2" value="1"/>
                    <count group_id="O3" value="4"/>
                    <count group_id="O4" value="3"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.7" spread="2.45"/>
                    <measurement group_id="O2" value="0.0" spread="NA">SD was not calculated for 1 participant.</measurement>
                    <measurement group_id="O3" value="4.0" spread="2.71"/>
                    <measurement group_id="O4" value="3.0" spread="1.73"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>78 hours after surgery</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="11"/>
                    <count group_id="O2" value="1"/>
                    <count group_id="O3" value="4"/>
                    <count group_id="O4" value="3"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.6" spread="2.62"/>
                    <measurement group_id="O2" value="0.0" spread="NA">SD was not calculated for 1 participant.</measurement>
                    <measurement group_id="O3" value="4.5" spread="2.08"/>
                    <measurement group_id="O4" value="3.3" spread="2.08"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>84 hours after surgery</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="11"/>
                    <count group_id="O2" value="1"/>
                    <count group_id="O3" value="4"/>
                    <count group_id="O4" value="3"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.5" spread="3.32"/>
                    <measurement group_id="O2" value="1.0" spread="NA">SD was not calculated for 1 participant.</measurement>
                    <measurement group_id="O3" value="5.0" spread="1.15"/>
                    <measurement group_id="O4" value="3.0" spread="2.65"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>96 hours after surgery</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="11"/>
                    <count group_id="O2" value="1"/>
                    <count group_id="O3" value="4"/>
                    <count group_id="O4" value="3"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.4" spread="1.81"/>
                    <measurement group_id="O2" value="0.0" spread="NA">SD was not calculated for 1 participant.</measurement>
                    <measurement group_id="O3" value="3.5" spread="1.29"/>
                    <measurement group_id="O4" value="3.3" spread="3.06"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 8 after discharge</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="11"/>
                    <count group_id="O2" value="1"/>
                    <count group_id="O3" value="4"/>
                    <count group_id="O4" value="3"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.1" spread="2.20"/>
                    <measurement group_id="O2" value="1.0" spread="NA">SD was not calculated for 1 participant.</measurement>
                    <measurement group_id="O3" value="4.8" spread="1.71"/>
                    <measurement group_id="O4" value="3.3" spread="3.06"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 15 after discharge</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="11"/>
                    <count group_id="O2" value="1"/>
                    <count group_id="O3" value="4"/>
                    <count group_id="O4" value="3"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.6" spread="1.77"/>
                    <measurement group_id="O2" value="0.0" spread="NA">SD was not calculated for 1 participant.</measurement>
                    <measurement group_id="O3" value="3.8" spread="2.99"/>
                    <measurement group_id="O4" value="2.7" spread="2.31"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 29 after discharge</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="11"/>
                    <count group_id="O2" value="0"/>
                    <count group_id="O3" value="4"/>
                    <count group_id="O4" value="1"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.5" spread="1.97"/>
                    <measurement group_id="O3" value="0.5" spread="0.58"/>
                    <measurement group_id="O4" value="0.0" spread="NA">SD was not calculated for 1 participant.</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants by Patient Global Assessment (PGA) of Pain Control Score Categories</title>
        <description>The participant assessed their overall pain control in the past 24 hours using the PGA 4-point scale where: 0=poor, 1=fair, 2=good and 3=excellent.</description>
        <time_frame>Days 5, 8, 15 and 29</time_frame>
        <population>mITT population included all randomized and treated participants with at least one post-injection pain score.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Placebo (sterile saline solution 0.9% Sodium Chloride Injection) injected into RA muscles during abdominoplasty surgery.</description>
          </group>
          <group group_id="O2">
            <title>Botulinum Neurotoxin Serotype E Dose 1</title>
            <description>Single botulinum neurotoxin serotype E Dose 1 injection into RA muscles during abdominoplasty surgery.</description>
          </group>
          <group group_id="O3">
            <title>Botulinum Neurotoxin Serotype E Dose 2</title>
            <description>Single botulinum neurotoxin serotype E Dose 2 injection into RA muscles during abdominoplasty surgery.</description>
          </group>
          <group group_id="O4">
            <title>Botulinum Neurotoxin Serotype E Dose 3</title>
            <description>Single botulinum neurotoxin serotype E Dose 3 injection into RA muscles during abdominoplasty surgery.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants by Patient Global Assessment (PGA) of Pain Control Score Categories</title>
          <description>The participant assessed their overall pain control in the past 24 hours using the PGA 4-point scale where: 0=poor, 1=fair, 2=good and 3=excellent.</description>
          <population>mITT population included all randomized and treated participants with at least one post-injection pain score.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="11"/>
                <count group_id="O2" value="1"/>
                <count group_id="O3" value="4"/>
                <count group_id="O4" value="3"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Day 5</title>
              <category_list>
                <category>
                  <title>PGA score 3</title>
                  <measurement_list>
                    <measurement group_id="O1" value="7"/>
                    <measurement group_id="O2" value="1"/>
                    <measurement group_id="O3" value="2"/>
                    <measurement group_id="O4" value="1"/>
                  </measurement_list>
                </category>
                <category>
                  <title>PGA score 2</title>
                  <measurement_list>
                    <measurement group_id="O1" value="4"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="2"/>
                    <measurement group_id="O4" value="1"/>
                  </measurement_list>
                </category>
                <category>
                  <title>PGA score 1</title>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="1"/>
                  </measurement_list>
                </category>
                <category>
                  <title>PGA score 0</title>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 8</title>
              <category_list>
                <category>
                  <title>PGA score 3</title>
                  <measurement_list>
                    <measurement group_id="O1" value="7"/>
                    <measurement group_id="O2" value="1"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="1"/>
                  </measurement_list>
                </category>
                <category>
                  <title>PGA score 2</title>
                  <measurement_list>
                    <measurement group_id="O1" value="4"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="2"/>
                    <measurement group_id="O4" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>PGA score 1</title>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="1"/>
                    <measurement group_id="O4" value="2"/>
                  </measurement_list>
                </category>
                <category>
                  <title>PGA score 0</title>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="1"/>
                    <measurement group_id="O4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 15</title>
              <category_list>
                <category>
                  <title>PGA score 3</title>
                  <measurement_list>
                    <measurement group_id="O1" value="8"/>
                    <measurement group_id="O2" value="1"/>
                    <measurement group_id="O3" value="2"/>
                    <measurement group_id="O4" value="1"/>
                  </measurement_list>
                </category>
                <category>
                  <title>PGA score 2</title>
                  <measurement_list>
                    <measurement group_id="O1" value="3"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="1"/>
                    <measurement group_id="O4" value="1"/>
                  </measurement_list>
                </category>
                <category>
                  <title>PGA score 1</title>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="1"/>
                    <measurement group_id="O4" value="1"/>
                  </measurement_list>
                </category>
                <category>
                  <title>PGA score 0</title>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 29</title>
              <category_list>
                <category>
                  <title>PGA score 3</title>
                  <measurement_list>
                    <measurement group_id="O1" value="9"/>
                    <measurement group_id="O2" value="1"/>
                    <measurement group_id="O3" value="3"/>
                    <measurement group_id="O4" value="1"/>
                  </measurement_list>
                </category>
                <category>
                  <title>PGA score 2</title>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="1"/>
                    <measurement group_id="O4" value="2"/>
                  </measurement_list>
                </category>
                <category>
                  <title>PGA score 1</title>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>PGA score 0</title>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Doses of Rescue Medications Used</title>
        <time_frame>Up to 96 hours postsurgery</time_frame>
        <population>mITT population included all randomized and treated participants with at least one post-injection pain score.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Placebo (sterile saline solution 0.9% Sodium Chloride Injection) injected into RA muscles during abdominoplasty surgery.</description>
          </group>
          <group group_id="O2">
            <title>Botulinum Neurotoxin Serotype E Dose 1</title>
            <description>Single botulinum neurotoxin serotype E Dose 1 injection into RA muscles during abdominoplasty surgery.</description>
          </group>
          <group group_id="O3">
            <title>Botulinum Neurotoxin Serotype E Dose 2</title>
            <description>Single botulinum neurotoxin serotype E Dose 2 injection into RA muscles during abdominoplasty surgery.</description>
          </group>
          <group group_id="O4">
            <title>Botulinum Neurotoxin Serotype E Dose 3</title>
            <description>Single botulinum neurotoxin serotype E Dose 3 injection into RA muscles during abdominoplasty surgery.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Doses of Rescue Medications Used</title>
          <population>mITT population included all randomized and treated participants with at least one post-injection pain score.</population>
          <units>doses</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="11"/>
                <count group_id="O2" value="1"/>
                <count group_id="O3" value="4"/>
                <count group_id="O4" value="3"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Oxycodone</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="9.7" spread="5.92"/>
                    <measurement group_id="O2" value="5.0" spread="NA">SD was not calculated for 1 participant.</measurement>
                    <measurement group_id="O3" value="11.8" spread="5.68"/>
                    <measurement group_id="O4" value="11.7" spread="4.93"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Opioid</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="14.2" spread="7.40"/>
                    <measurement group_id="O2" value="8.0" spread="NA">SD was not calculated for 1 participant.</measurement>
                    <measurement group_id="O3" value="15.8" spread="6.90"/>
                    <measurement group_id="O4" value="16.0" spread="6.08"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Up to 31 days</time_frame>
      <desc>Safety Population included all participants exposed to any amount of study drug.</desc>
      <group_list>
        <group group_id="E1">
          <title>Placebo</title>
          <description>Placebo (sterile saline solution 0.9% Sodium Chloride Injection) injected into RA muscles during abdominoplasty surgery.</description>
        </group>
        <group group_id="E2">
          <title>Botulinum Neurotoxin Serotype E Dose 1</title>
          <description>Single botulinum neurotoxin serotype E Dose 1 injection into RA muscles during abdominoplasty surgery.</description>
        </group>
        <group group_id="E3">
          <title>Botulinum Neurotoxin Serotype E Dose 2</title>
          <description>Single botulinum neurotoxin serotype E Dose 2 injection into RA muscles during abdominoplasty surgery.</description>
        </group>
        <group group_id="E4">
          <title>Botulinum Neurotoxin Serotype E Dose 3</title>
          <description>Single botulinum neurotoxin serotype E Dose 3 injection into RA muscles during abdominoplasty surgery.</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="3"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="3"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <default_vocab>19.1</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="8" subjects_at_risk="12"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="4"/>
                <counts group_id="E3" subjects_affected="4" subjects_at_risk="4"/>
                <counts group_id="E4" subjects_affected="3" subjects_at_risk="3"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="12"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="4"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="4"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="3"/>
              </event>
              <event>
                <sub_title>Constipation</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="12"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="4"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="4"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="3"/>
              </event>
              <event>
                <sub_title>Vomiting</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="12"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="4"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="4"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="3"/>
              </event>
              <event>
                <sub_title>Dyspepsia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="4"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="3"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Immune system disorders</title>
            <event_list>
              <event>
                <sub_title>Food allergy</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="12"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="3"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Tooth infection</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="12"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="3"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Seroma</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="4"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="3"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>Transaminases increased</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="4"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="3"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Back pain</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="12"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="4"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="3"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="12"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="4"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="4"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="3"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Depressed mood</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="4"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="3"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Reproductive system and breast disorders</title>
            <event_list>
              <event>
                <sub_title>Vaginal haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="4"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="3"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Hypoxia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="12"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="3"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Pruritus</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="4"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="4"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="3"/>
              </event>
              <event>
                <sub_title>Pruritus generalised</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="4"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="3"/>
              </event>
              <event>
                <sub_title>Rash</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="12"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="3"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>A disclosure restriction on the PI is that the sponsor can review results communications prior to public release and can embargo communications regarding trial results for a period that is less than or equal to 90 days from the time submitted to the sponsor for review. The sponsor cannot require changes to the communication and cannot extend the embargo.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Therapeutic Area, Head</name_or_title>
      <organization>Allergan</organization>
      <phone>714-246-4500</phone>
      <email>clinicaltrials@allergan.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

